References
1. KD. Tripathi. Chemotherapy of Neoplastic Diseases. Essentials of Medical Pharmacology. 7th Edition. Page – 872.
2. Nazma Hanif, Faiz Anwer. Rituximab. StatPearls. NIH. National Library of Medicine. National Center for Biotechnology Information. PMC. PubMed central. September 2022. [Accessed on 28th January 2023] https://www.ncbi.nlm.nih.gov/books/NBK564374/
3. Roche Products Ltd. MabThera 100 mg and 500 mg concentrate solution for infusion. Rituximab. Electronics Medicines Compendium. [Revised in January 2022]. [Accessed on 28th January 2023] https://www.medicines.org.uk/emc/files/pil.3801.pdf
4. Biogen and Genentech USA, Inc. RITUXAN® (rituximab) injection, for intravenous use. U.S. Food and Drug Administration. [Revised in December 2021]. [Accessed on 28th January 2023] https://www.gene.com/download/pdf/rituxan_prescribing.pdf
5. Biogen and Genentech USA, Inc. Rituxan. Rituximab. [Accessed on 28th January 2023] https://www.rituxan.com/
6. Central Drugs Standard Control Organization. Rituximab (finished formulation import). July 2000. [Accessed on 28th January 2023] https://cdscoonline.gov.in/CDSCO/Drugs
Disclaimer
Singhla Medicos’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Singhla Medicos. Our mission is to support, not replace, the doctor-patient relationship.
Reviews
There are no reviews yet.